A new obesity drug called retatrutide pushed trial patients to lose nearly a quarter of their body weight in less than a year, and doctors are calling the numbers the biggest leap since Ozempic hit the market.
Quick Take
- A Phase 2 trial found patients on the highest dose of retatrutide lost 24.2% of body weight at 48 weeks, far above the placebo group’s 2.1%.
- A later Phase 3 study reported an average 28.7% weight loss at 68 weeks in obese patients with knee osteoarthritis.
- Every major retatrutide trial compared the drug to a placebo or to dulaglutide, not to Ozempic’s active ingredient, semaglutide.
- Maker Eli Lilly has not yet published full peer-reviewed data or sought approval, so the drug remains experimental.
What The Trial Data Actually Shows
Retatrutide is built differently than Ozempic. It targets three gut hormone receptors instead of one, which researchers believe drives bigger results. In the New England Journal of Medicine trial, patients taking 12 milligrams lost an average of 24.2% of their starting weight after 48 weeks, compared with just 2.1% for those on placebo. Eighty-three percent of that top-dose group lost at least 15% of their body weight.
Those numbers come from a mid-stage study of 338 adults with obesity who did not have type 2 diabetes. A separate diabetes-focused trial, published in The Lancet, found smaller but still notable results: up to 16.9% weight loss at 36 weeks, well above the placebo and dulaglutide comparison groups. Eli Lilly later announced Phase 3 results showing a 28.7% average weight loss at 68 weeks in patients with obesity and knee osteoarthritis.
Why The Ozempic Comparison Gets Tricky
Here is the catch headlines tend to skip. None of these trials actually put retatrutide head-to-head against Ozempic or its sister drug Wegovy. The obesity study used a placebo. The diabetes study used dulaglutide, a different medicine entirely. Comparing percentages across separate trials is common in medicine, but it is not the same as a direct contest between two drugs in the same room.
That matters because trial populations, dosing schedules, and study lengths all differ. A drug that beats placebo by 22 points in one study and another drug that beats placebo by 15 points in a different study cannot be stacked side by side with full confidence. Researchers call this cross-trial comparison, and it is useful for forming hypotheses, not for declaring a winner outright.
A Pattern Seen Before With Tirzepatide
This is not a new story in obesity medicine. Tirzepatide, sold as Zepbound and Mounjaro, went through the exact same cycle. Early separate trials suggested it beat semaglutide, and headlines ran with it. Eventually a real head-to-head trial confirmed the edge, showing tirzepatide users lost 20.2% of body weight at 72 weeks versus 13.7% for semaglutide users. Retatrutide is now sitting at the stage tirzepatide once occupied, with strong numbers but no finished direct matchup against Ozempic yet.
One review comparing retatrutide, tirzepatide, and semaglutide side by side across multiple studies found average weight loss figures of 24.1% for retatrutide, 31.6% for tirzepatide, and 19.7% for semaglutide. Those figures come from pooled analysis rather than one single trial, which is a reminder that the full comparative picture is still forming as more data rolls in from ongoing research programs.
What Comes Next Before Any Drugstore Shelf
Retatrutide has not been approved by regulators and is not available by prescription. Eli Lilly has not released the complete peer-reviewed Phase 3 report, including full safety tables and dropout data, which independent scientists will need before drawing firm conclusions. Approval would require the Food and Drug Administration to review that complete data package, not just the investor announcement that introduced the 28.7% figure.
The bottom line for patients watching this space: the weight-loss numbers are real and come from legitimate, published, placebo-controlled research. What remains unsettled is the direct Ozempic comparison, the long-term safety record, and final regulatory sign-off. Those answers will take more trials, more time, and more transparency from the company running them.
Sources:
yahoo.com, investor.lilly.com, thelancet.com
